Candidate was developed on firm’s UCB-1™ platform.



Cytovance Biologics will aid Bone Biologics in process development and cGMP manufacturing of its recombinant protein for spinal fusion surgery.


Bone Biologic’s candidate was developed on its UCB-1™ protein-based technologies for bone and cartilage regeneration. The platform has applications in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine, according to the company.


The Bone Biologics’ project is being executed out of Cytovance’s multiproduct cGMP production facility in Oklahoma City. The 44,000-sq-ft facility specializes in the clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L (w/v) from both fed-batch and perfusion processes.








This site uses Akismet to reduce spam. Learn how your comment data is processed.